Objective-APOA5 variants are strongly associated with hypertriglyceridemia, as well as increased risks of cardiovascular disease and acute pancreatitis. Hypertriglyceridemia in apo AV dysfunction often aggravates by environmental factors such as highcarbohydrate diets or aging. To date, the molecular mechanisms by which these environmental factors induce hypertriglyceridemia are poorly defined, leaving the high-risk hypertriglyceridemia condition undertreated. −/− mice. Further mechanistic studies revealed that in response to these environmental factors, SREBP-1c was activated to increase triglyceride synthesis and to permit the incorporation of triglyceride into abnormally large-VLDL particles, which require apo AV for efficient clearance. Conclusions-Severe hypertriglyceridemia develops only when genetic factors (apo AV deficiency) and environmental effects (SREBP-1c activation) coexist. We demonstrate that the regulated production of large-sized VLDL particles via SREBP-1c determines plasma triglyceride levels in apo AV deficiency. Our findings explain the long-standing enigma of the late-onset hypertriglyceridemia phenotype of apo AV deficiency and suggest a new approach to treat hypertriglyceridemia by targeting genes that mediate environmental effects. Visual Overview-An online visual overview is available for this article.
H ypertriglyceridemia arises from the accumulation of TRLs (triglyceride-rich lipoproteins) in the circulation. 1 Triglycerides of exogenous and endogenous origins are secreted from intestine and liver in the form of chylomicrons and VLDLs (very low-density lipoprotein), respectively. These lipoprotein-triglycerides are hydrolyzed by LPL (lipoprotein lipase) in the circulation to liberate free fatty acids as energy sources for peripheral tissues. Severe hypertriglyceridemia increases the risk of acute pancreatitis, whereas moderate hypertriglyceridemia increases the risk of cardiovascular diseases. Recent genome-wide association studies uncovered an association between plasma triglyceride levels and cardiovascular disease risk with the hypertriglyceridemia pathway genes, such as apo CIII (APOC3), angiopoietin-like 3 (ANGPTL3), angiopoietin-like 4 (ANGPTL4), asialoglycoprotein receptor 1 (ASGR1), LPL, and apolipoprotein A-V (APOA5). [2] [3] [4] In spite of these advances, effective therapeutic modalities to rescue hypertriglyceridemia are limited, and a better understanding of plasma triglyceride metabolism is warranted. 5 Severe hypertriglyceridemia, defined as plasma triglyceride levels >1000 mg/dL, can be classified into monogenic and polygenic types. 5 Monogenic hypertriglyceridemia (MIM 238600) is a rare (1 in 1 000 000) disorder with early-onset in infancy or childhood and caused by monogenic defects in LPL pathway genes, such as LPL, apo CII (APOC2), glycosylphosphatidylinositol-anchored HDL (high-density lipoprotein)-binding protein 1 (GPIHBP1), LPL chaperone lipase maturation factor 1 (LMF1), and APOA5. Polygenic hypertriglyceridemia (MIM 144650) is a more common (1 in 600), late-onset disorder, which typically results from the accumulation of multiple genetic variants in LPL pathway genes. In either type, the severe hypertriglyceridemia develops by the combination of genetic plus environmental/ secondary factors (eg, high-carbohydrate, lipid-rich diets, aging, obesity, diabetes mellitus, and excess alcohol intake). 6 Previous work has demonstrated that the accumulation of VLDL in response to these factors contributes to the development of severe hypertriglyceridemia. 7 In vivo kinetic studies have further implicated the contribution of the increased production of large-sized VLDL particles. 8, 9 However, a molecular understanding of how environmental factors induce VLDL accumulation remains elusive in the sense that few studies have successfully identified a single gene that dominantly mediates the environmental effects of severe hypertriglyceridemia.
APOA5 encodes apo AV, which is secreted from the liver and circulates on chylomicrons, VLDLs, and HDLs. 10, 11 Apo AV reduces plasma triglyceride levels primarily by stimulating the LPL-mediated plasma triglyceride clearance. [12] [13] [14] [15] Apo AV binds both TRL and HSPG/GPIHBP1 that tethers LPL on endothelial surfaces, thereby facilitating the interaction between TRLs and LPL. [12] [13] [14] Apo AV has alternative functions to enhance the whole cell uptake of TRLs via its ligand activities for lipoprotein receptors 13, 16, 17 or to inhibit VLDL synthesis via its intracellular role to promote lipid droplet formation. 18, 19 The dominant role of apo AV in regulating plasma triglyceride levels in humans has been documented from the severe hypertriglyceridemia phenotype in patients with APOA5 deficiency (MIM 606368). 20, 21 As in severe hypertriglyceridemia of other genetic causes, 6 severe hypertriglyceridemia in APOA5 deficiency often develops in response to environmental/secondary factors, such as high-carbohydrate diets, lipid-rich diets, diabetes mellitus, and aging. [20] [21] [22] [23] Molecular understanding of the environment-induced hypertriglyceridemia in apo AV deficiency could lead to the development of new therapeutic options to treat severe hypertriglyceridemia by intervening the gene-environment interactions.
Mice deficient in apo AV (Apoa5 −/− ) has been described previously.
11 Apoa5 −/− mice manifest only moderate hypertriglyceridemia (≈400 mg/dL) on a chow diet. In humans, patients with APOA5 deficiency manifest variable levels of plasma triglyceride, and severe hypertriglyceridemia (≈6000 mg/dL) often develops in response to environmental/secondary factors as discussed above. [20] [21] [22] [23] Although this discrepancy has been commonly interpreted as a species difference, we rather reasoned that Apoa5 −/− mice might serve as a useful model to identify the environmental/secondary factors that induce severe hypertriglyceridemia and to explore its underlying mechanisms in vivo.
Here, we thoroughly examined the environmental factors that induce severe hypertriglyceridemia in human APOA5 deficient subjects in Apoa5 −/− mice. We found that severe hypertriglyceridemia was induced in Apoa5 −/− mice either by (1) administration of T0901317, a synthetic pharmacological activator of LXR (liver X receptor); (2) ). Further study demonstrated that the activation of SREBP-1c is required to increase triglyceride synthesis and to permit the incorporation of triglyceride into abnormally large-VLDL particles, which require apo AV for efficient clearance. The apo AV-SREBP-1c interplay expands our understanding of the gene-environment interaction in the pathogenesis of severe hypertriglyceridemia, suggesting the potential therapeutic approach to treat hypertriglyceridemia by targeting the SREBP-1c large-VLDL pathway that mediates the environmental effects.
Methods
The authors declare that all supporting data are available within the article (and its online-only Data Supplement). 27 For dietary studies, a rodent diet high in fructose (69 kcal% fructose, 10 kcal% fat, 20 kcal% protein; No. D08040107; Research Diets, Inc) was used. For olive-oil gavage studies, 16-hour fasted mice were given oral gavage of olive oil (300 μL/body), after the pretreatment with intraperitoneal injection of normal saline or Triton WR-1339 (500 mg/kg body weight). 28 For all the animal studies, blood was drawn from the retroorbital sinus with heparinized capillary tubes, and plasma was separated immediately 
Animals

Apoa5
Biochemical Analyses
Plasma levels of cholesterol and triglycerides were measured enzymatically as described previously using kits. 29 Plasma levels of insulin were assayed with the mouse insulin ELISA kits (Ultra Sensitive Rat Insulin ELISA Kit from Crystal Chem, Inc; Morinaga, Tokyo, Japan) as described.
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Fast Performance Liquid Chromatography
For fast performance liquid chromatography (FPLC) in Figures 1C,  1D and 5E, pooled plasma (1.7 mL) of each group of mice in Figures 1A, 1B , and 5D, respectively, was subjected to ultracentrifugation at a density of 1.215 g/mL. Plasma of all mice in the same group was pooled. The resulting lipoprotein fractions (density <1.215) were adjusted to a final volume of 3 mL with a buffer containing 0.15 M sodium chloride, 0.01% (wt/vol) sodium EDTA, and 0.02% (wt/vol) sodium azide at pH 7.2, after which 2 mL was subjected to fast performance liquid chromatography using a Superose 6B column. Fractions (2 mL) were collected, and 0.1 mL from each fraction was used to determine the content of total cholesterol and triglycerides.
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High-Performance Liquid Chromatography
The size distribution of plasma lipoproteins was analyzed by gel-permeation high-performance liquid chromatography (HPLC) system as described previously 31 (LipoSEARCH; Skylight Biotech, Inc, Akita, Japan). Briefly, plasma lipoproteins were separated with tandemly connected gel-permeation columns, and triglyceride levels in the column effluent were measured and expressed in mV. Lipoproteins were classified on the basis of their particle sizes by component peak analyses with the gaussian curve fitting technique. The ranges of eluting positions for major lipoproteins are as follows chylomicron or large-VLDL (>80 nm), [15] [16] [17] [18] [19] 
Apolipoprotein Analyses of Plasma VLDL
Plasma VLDL (density <1.006 g/mL) was isolated from the pooled plasma of each group of mice by ultracentrifugation. The protein concentrations in VLDL were measured as described previously. 27 VLDLs (6 μg protein) from each group were delipidated with ethanol/ether (1:1), precipitated, and dissolved in sodium dodecyl sulfate (SDS) loading buffer. Equal amounts of VLDL protein (7.5 ng per lane) were subjected to 4% to 15% SDS gradient gels and immunoblot analyses using primary antibodies at a dilution of 1:1000 (anti-apoB and apoE antibody, No. K23300R; Biodesign International, Saco, ME).
Electron Microscopy of Plasma VLDL
Plasma VLDL (density <1.006 g/mL) was isolated from the pooled plasma of each group of mice by ultracentrifugation. VLDL fractions were negatively stained and visualized by electron microscopy. The diameters of VLDL particles were measured by ImageJ 1.39u software (National Institutes of Health) as described previously.
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Quantitative Real-Time Polymerase Chain Reaction Analysis Total RNA was prepared from mouse livers using a TRIzol reagent (Invitrogen Corp, Tokyo, Japan) and subjected to quantitative realtime polymerase chain reaction as previously described. 24, 29 The relative amounts of mRNAs were calculated using the comparative threshold cycle method. Mouse cyclophilin mRNA was used as the invariant control. Most of the primers for real-time polymerase chain reaction analysis were described previously. 24, 27 The primers used for the measurement of individual mRNAs are available on request.
Recombinant Adenoviruses
Recombinant adenoviruses that express β-galactosidase (lacZ) or APOA5 under the control of the cytomegalovirus promoter were constructed using the pAd/cytomegalovirus/V5-DEST Gateway system (Invitrogen Corp) as described previously. 32 The recombinant adenoviruses were expanded in HEK293 (human embryonic kidney) cells, purified by cesium chloride ultracentrifugation, and stored in 10% (v/v) glycerol in PBS at −80°C. A total of 0.5×10 11 particles of lacZ virus (adenoviruses encoding lacZ [Ad-lacZ]) or APOA5 virus (adenovirus carrying human APOA5 [Ad-APOA5]) were injected into the jugular vein of mice anesthetized with 60 mg/kg of sodium pentobarbital.
Hepatic VLDL-Triglyceride Secretion
Secretion rates of VLDL-triglyceride in vivo were estimated by the intravenous administration of Triton WR-1339 as described previously. 28 Briefly, mice were fasted overnight (16 hours) before intravenous injection of Triton WR-1339 (500 mg/kg body weight). Plasma was obtained by retro-orbital bleeding at the indicated time points after injection. Plasma triglyceride levels were measured as described above.
Effect of Heparin on Chylomicron Clearance
Apoa5
−/− mice (11-16 weeks old, male) were fasted for 16 hours, followed by gavage with olive oil (10 μL/g-body weight). Four hours after the gavage, mice were randomly assigned to a group injected with normal saline (100 μL/body) or a group injected with heparin (50 IU/100 μL/body). Aliquots of blood were obtained by retroorbital bleeding at the indicated time points (0, 3, 15, 30, 120 minutes) and used to determine the plasma levels of triglycerides.
Measurement of Plasma Lipase Activities
Activities of LPL and HL (hepatic lipase) in postheparin plasma were determined as described. 33, 34 Postheparin plasma was collected after injection of heparin (50 IU/100 μL/body) via the jugular vein at the indicated time points. 35 To eliminate the possible contamination of plasma VLDL-triglyceride into the lipase assay reaction, plasma was ultracentrifuged at 48 000 rpm (204 782 g) for 16 hours to remove the VLDL fraction (top). An aliquot of the bottom fraction (equivalent to 5 μL of plasma) was then diluted in a final 100 μL normal saline solution and used as an enzymatic source in the lipase activity assay. 34 LPL activity was calculated by subtracting the HL activity (assayed in the presence of 1M NaCl) from the total lipase activity (assayed in the absence of 1M NaCl) as described. 34 
Statistical Analyses
All values are given as mean±SEM. Statistical analyses were performed using PRISM 8 for Mac OS X (GraphPad Software, Inc; La Jolla, CA). Data were tested for normality and equal variance to confirm the appropriateness of parametric tests. Data that followed a normal distribution were analyzed by Student t test, Welch t test, 1-way ANOVA with Tukey post hoc test, or 2-way ANOVA with Tukey or Sidak post hoc tests, where appropriate. Data that failed normal distribution were analyzed by Mann-Whitney U test or by Kruskal-Wallis test with Dunn post hoc test. A P value of <0.05 was considered significant. Plasma from 5-7 mice of each group was pooled and subjected to ultracentrifugation at density (d)=1.215 g/mL. The lipoprotein fractions (d <1.215 g/mL) were subjected to gel filtration by FPLC, and the content of triglycerides in each fraction was measured as described in Methods. E-G, Electron microscopy of negatively stained plasma VLDL (very low-density lipoprotein; d <1.006 g/mL) from WT and Apoa5 −/− mice fed a chow diet with or without 0.015% T for 6 d. Plasma samples from 4 mice of each group were pooled, and VLDL was isolated for viewing by electron microscopy (E) as described in Methods. (Continued ) pharmacological conditions, where the production of large-VLDL particles are stimulated by LXR agonist (T0901317). Production of large-sized VLDLs has been suggested as a prominent feature of environment-induced hypertriglyceridemia, 8, 9 and we and others have previously demonstrated that the activation of SREBP1a, 30 LXR, 36 or LXR-SREBP-1c pathway, 27 produces large-sized VLDL particles of chylomicron size (>80 nm), which massively accumulates in the plasma of Ldlr −/− mice. The large-sized VLDL particles produced by LXR agonist has been shown to be of hepatic origin by primary hepatocyte study. 27 Immunoblot analyses of apo B 48 and apo B 100 in VLDL proteins ( Figure IA in the onlineonly Data Supplement) were compatible with the notion that LXR-induced large-VLDL particles are mainly of hepatic origin, as the apo B 48 to apo B 100 ratio of VLDL particles were not increased but decreased by T0901317 treatment.
Results
LXR
On chow-fed condition, these mice exhibited a moderate increase in plasma triglyceride 11 Elevated levels of plasma triglycerides are confined to VLDL fraction as revealed by fast performance liquid chromatography ( Figure 1C and 1D, chow) . Notably, the median size of plasma VLDL particles (density <1.006) in Apoa5 −/− (39.2 nm) is slightly larger than in WT mice (36.5 nm) as determined by negative stain electron microscopy ( Figure 1E-1G, chow) , which is consistent with previous reports. 16, 37 Treatment of mice with T0901317 resulted in a robust increase in the mRNA expression of SREBP-1c and its target genes in both WT and Apoa5 −/− mice, which is consistent with previous reports 27 (data not shown). When Apoa5 −/− mice were treated with T0901317, they exhibited a massive increase in plasma triglycerides, reaching over 4000 mg/dL ( Figure 1A) , accompanying a modest increase in plasma cholesterol levels ( Figure 1B) . In clear contrast, in the presence of apo AV, WT mice treated with T0901317 exhibited an only modest increase in plasma triglyceride ( Figure 1A ) and a mild increase in plasma cholesterol ( Figure 1B) . Fast performance liquid chromatography analysis revealed that the elevated triglycerides in Apoa5 −/− were contained in VLDL particles ( Figure 1D ). T0901317 increased the size of VLDL particles in WT mice, where the median size of VLDL particles increased from 36.5 to 49.6 nm ( Figure 1E and 1F) , 27, 36 which is more pronounced in Apoa5 −/− (39.2 to 58.2 nm; Figure 1E and 1G). The percentage of the large-sized VLDL particles of chylomicron size (>80 nm) was increased in WT (1.4% to 12.8%; Figure 1F ), which is again more pronounced in Apoa5 −/− mice (2.8% to 17.5%; Figure 1G ).
These results suggest that large-sized VLDL particles are removed from the plasma in the presence of apo AV but not efficiently in the absence of apo AV.
Large-Sized VLDL Particles Are Cleared by Apo AV
To determine if apo AV clears the large-sized VLDL particles from plasma, we overexpressed apo AV in several models of large-VLDL accumulation by using recombinant Ad-APOA5. We first confirmed the triglyceride-lowering effect of Ad-APOA5 in Apoa5 −/− mice. Severe hypertriglyceridemia was induced by 6 days of T0901317 treatment in
, which was reversed 3 days after the injection of Ad-APOA5 but not after the control virus injection (Ad-lacZ, 4849±977 mg/dL versus Ad-APOA5, 485±122 mg/ dL, P<0.05 by Welch t test). We next tested another model of large-VLDL accumulation (Ldlr −/− ;T0901317). 27 As shown in Figure 2 , the overexpression of human APOA5 by recombinant adenovirus resulted in a rapid reduction of plasma triglyceride levels ( Figure 2A ) accompanying a delayed reduction in plasma TC levels ( Figure 2B 
bp-1c −/−
; Figure 3B and Figure 3B and 3C ). These results demonstrate the essential role of the SREBP-1c large-VLDL pathway in severe hypertriglyceridemia induced by LXR agonist in apo AV deficiency.
Carbohydrate-Induced Hypertriglyceridemia and Its Rescue by SREBP-1c Deficiency
The important unanswered question here is if the SREBP-1c large-VLDL pathway plays a dominant role in the development of severe hypertriglyceridemia in pathophysiological conditions. To this end, we thoroughly tested for environmental factors that induce severe hypertriglyceridemia in patients with human APOA5 deficiency 22, 23 (Figures 4 and 5 ). ; −/− mice to high-fructose feeding over a 14 days period. When WT mice were fed a high-fructose diet (69 kcal% fructose), they showed a marginal increase in plasma triglyceride as well as plasma cholesterol ( Figure 4A and 4B) . In marked contrast, we discovered that Apoa5 −/− mice treated with a high-fructose diet exhibited a massive increase in plasma triglycerides, reaching ≈3000 mg/dL at day 14, accompanying a mild increase in plasma cholesterol ( Figure 4A , P<0.001, 2-way ANOVA; Figure 4B , P<0.001, 2-way ANOVA).
Next, we tested the role of SREBP-1c in this fructoseinduced hypertriglyceridemia of apo AV deficiency. Previous work demonstrated that high-fructose feeding induces hepatic lipogenesis partially via SREBP-1c. 38 Table) .
The deletion of SREBP-1c produced the more pronounced effect on the plasma triglyceride levels: SREBP-1c deficiency nearly completely rescued the fructose-induced hypertriglyceridemia in Apoa5 −/− mice ( Figure 4C , P<0.0001, 2-way ANOVA). The complete rescue of the hypertriglyceridemia phenotype by SREBP-1c deficiency can be explained if SREBP-1c is essential for the production of large-VLDL particles not only by LXR agonist treatment ( Figure 3 In the experiments not shown, we tested the effect of highglucose and high-sucrose feeding and found no increase in plasma triglyceride levels in Apoa5 −/− ;Srebp-1c −/− mice by any of these high-carbohydrate diets (data not shown).
Collectively, these results reveal the essential role of the SREBP-1c large-VLDL pathway in severe hypertriglyceridemia induced by various carbohydrates.
SREBP-1c Deficiency Does Not Affect Chylomicron Accumulation in Apoa5 −/− Mice
Another diet that induces severe hypertriglyceridemia in human APOA5 deficiency is a lipid-rich diet. As shown in Table I in the online-only Data Supplement. CM indicates chylomicron; HDL, high-density lipoprotein; and LDL, low-density density lipoprotein. Figure 5A (top, left) , olive oil gavage in WT mice resulted in a transient increase in plasma triglyceride levels that returned to baseline after 8 hours, reflecting the production of chylomicron particles followed by rapid clearance. In marked contrast, olive-oil gavage in Apoa5 −/− mice resulted in a massive and persistent increase in the plasma triglyceride levels, reaching over 5000 mg/dL after 8 hours ( Figure 5A , top, left; P<0.0001 by 2-way ANOVA). When these mice were pretreated with Triton WR-1339, an inhibitor of LPL-mediated triglyceride lipolysis, olive oil gavage induced chylomicron accumulation both in WT and Apoa5 −/− mice at similar rates to similar levels, demonstrating the role of apo AV in LPL-mediated chylomicron-triglyceride clearance ( Figure 5A , top, right). Previous work suggested that apo AV stimulates LPL pathway by enhancing the interaction between TRL and LPL via its dual binding affinity for TRL and GPIHBP1/HSPGs that tether LPL on endothelial cell surfaces. [12] [13] [14] If this is the case, one would expect that heparin injection would rescue TRL accumulation in apo AV deficiency by releasing LPL from endothelial cell surfaces into circulation and restoring the interaction between LPL and TRL. As expected, the administration of heparin to olive oil-fed Apoa5 −/− mice rapidly cleared preaccumulated chylomicron-triglyceride ( Figure IC in the onlineonly Data Supplement; P<0.0001, 2-way ANOVA). Heparin injection also cleared preaccumulated VLDL-triglyceride in Apoa5 −/− mice ( Figure ID in the online-only Data Supplement). Importantly, heparin-releasable LPL activity was not decreased in Apoa5 −/− compared with WT mice ( Figure IE in the onlineonly Data Supplement). These results support the notion that apo AV deficiency decreases the substrate (TRL)-enzyme (LPL) interaction but not the amount of enzyme (the heparinreleasable activity of LPL protein). We next tested the role of SREBP-1c in chylomicron metabolism of Apoa5 −/− mice. In marked contrast to the rescue of VLDL accumulation in Apoa5 −/− by SREBP-1c deficiency (Figures 3 and 4) , the rates of chylomicron accumulation were not affected by SREBP-1c deletion either in the presence or absence of Triton WR-1339 ( Figure 5A, lower) , indicating that SREBP-1c deficiency affects neither clearance nor production of chylomicrons after a fat load. These results suggest that SREBP-1c controls VLDL levels at least partially by regulating the size of VLDL particles, without directly affecting chylomicron production or the chylomicron/VLDL removal system.
Age-Related Hypertriglyceridemia in Apoa5 −/−
Mice and Its Rescue by the SREBP-1c Deletion
Lastly, we tested whether aging aggravates hypertriglyceridemia in Apoa5 −/− mice as is often observed in human APOA5 deficiency 22, 23 and, if so, whether the deletion of Srebp-1c could rescue the response. As shown, the age-related severe hypertriglyceridemia phenotype in human APOA5 deficiency (≈6000 mg/dL) was successfully reconstituted in Apoa5 −/− mice ( Figure 5B ). In Apoa5 −/− mice, aging severely increased the plasma triglyceride levels (8-17 weeks old, 959±118 mg/dL; 18-27 weeks old, 2019±193 mg/dL; >27 weeks old, 3362±388 mg/dL, Spearman r=0.6715; P<0.0001; Figure 5B ) and moderately increased the plasma TC levels (8-17 weeks old, 231±13 mg/dL; 18-27 weeks old, 328±16 mg/dL; >27 weeks old, 410±29 mg/dL, Spearman r=0.6059; P<0.0001; Figure 5C ). The plasma insulin levels also increased along with age ( Figure  IF Figure 5D and 5E). We isolated plasma VLDL from each group of aged mice in Figure 5D and 5E and measured the size of VLDL particles. As in younger mice (Figures 1  and 3) , plasma VLDL particles of Apoa5 −/− mice (median size, 39.9 nm; percentage of VLDL >80 nm, 4.0%) was larger than that of WT mice (36.5 nm and 1.6%, respectively), and this phenotype was abolished in Apoa5 −/− ; −/− mice (30.3 nm and 0.4%, respectively), suggesting that the SREBP-1c large-VLDL pathway may at least in part play a role in the rescue of age-related hypertriglyceridemia by SREBP-1c deficiency.
Together, these works clearly demonstrate the pivotal role of the SREBP-1c large-VLDL pathway in environmentinduced severe hypertriglyceridemia of apo AV deficiency (Figure 6 ). 
Discussion
In this report, we identify the pivotal role of the SREBP-1c large-VLDL pathway in the environment-induced hypertriglyceridemia using a disease mouse model. We found that SREBP-1c is required for the accumulation of VLDLs, but not chylomicrons, via its specific role in large-VLDL formation. Our main findings are summarized in Figure 6 . Without environmental stress, VLDLs and chylomicrons are scarce ( Figure 6A ). Under conditions where SREBP-1c is activated (LXR activation, high-carbohydrate diets, hyperinsulinemia, etc), large-VLDL particles are increasingly produced via SREBP-1c. As large TRL particles (large VLDL, chylomicron) require apo AV for efficient clearance (Figures 1-5 and Figure I in the online-only Data Supplement), these large VLDLs massively accumulate in Apoa5 −/− ( Figure 6B ). Without SREBP-1c, large-VLDL particles are not produced, resulting in clear rescue of severe hypertriglyceridemia ( Figure 6B ). However, SREBP-1c does not affect chylomicron metabolism ( Figure 6C ).
Several genes have been identified as causative genes of severe hypertriglyceridemia (LPL, APOC2, GPIHBP1, LMF1, and APOA5). 5 However, little is known about the genes that mediate environmental effects. The major drawback to investigate the gene-environment interactions has been the lack of suitable animal models. Although several different genetic mouse models of severe hypertriglyceridemia have been described previously (eg, Lpl ), these mice manifest severe hypertriglyceridemia without environmental stress 46, 47 or even neonatal death because of severe hypertriglyceridemia at birth. 44, 45, 47 As a suitable experimental model to study gene-environment interactions of severe hypertriglyceridemia, we focused on apo AV deficient mice, which are unique among other mouse models in that they are neither lethal nor severely hypertriglyceridemic at a younger age.
11 By using Apoa5 −/− mice, we successfully reconstituted the severe hypertriglyceridemic phenotype of human APOA5 deficiency in response to environmental stimuli, which enables us to delineate the underlying molecular mechanisms.
Severe hypertriglyceridemia is still an orphan disease with limited therapeutic options. 5 Newly developing approaches aim to target LPL pathway genes by inhibition (eg, antisense or monoclonal antibody against APOC3 or ANGPTL4) or overexpression (eg, adeno-associated virus for LPL). However, these modalities are costly and still under development before wide and safe clinical use. Targeting apo AV is promising: APOA5 variants are strongly associated with hypertriglyceridemia as well as cardiovascular disease risks 48, 49 and multiple studies in mice have demonstrated the potent triglyceride-lowering and atheroprotective effects of apo AV, albeit by overexpression methods (eg, recombinant proteins, adenovirus, adeno-associated virus, or transgenic animals 18, 50 ; Figure 2 ). Our results offer a novel approach to target apo AV pathway by inhibiting gene(s) that mediate the environmental effect ( Figure 6 ). Current therapy for environment-induced hypertriglyceridemia is only aimed at controlling environmental factors, which is often difficult to attain (strict fat/carbohydrate restriction, adequate control of diabetes mellitus) or impossible to manipulate (aging). Inhibition of SREBP-1c large-VLDL pathway provides a translatable approach to alleviate these environmental effects. Theoretically, reduction of VLDL by SREBP-1c inhibition may, in turn, decrease the level of chylomicron, inasmuch as VLDL and chylomicron compete for a common, saturable, plasma triglyceride removal system of LPL pathway. 6 Our studies may have relevance not only to severe hypertriglyceridemia but also to more common types of hypertriglyceridemia, such as postprandial or atherogenic dyslipidemia. Previous studies in humans have shown the association of APOA5 variants with postprandial hypertriglyceridemia after a high-fat meal. 51, 52 The indispensable role of apo AV in postprandial triglyceride clearance is clearly demonstrated in our data (Figures 4 and 5 , and Figure I in the online-only Data Supplement). Variants of APOA5 has also been shown to be associated with atherogenic dyslipidemia, which is characterized by a triad of hypertriglyceridemia, low HDL-cholesterol, and a predominance of small, dense LDL. 53, 54 Our data suggest that the accumulation of large VLDLs in the face of apo AV dysfunction (Figures 1-4 ) may increase small, dense LDLs, inasmuch as large VLDLs are the source of small, dense LDLs. 9 The well-known association between metabolic syndrome and small, dense LDLs 55 may be explained by the activation of SREBP-1c in metabolic syndrome. 42, 43 Inhibition of SREBP-1c has therapeutic potential for these common, atherogenic type of dyslipidemia.
The current studies advance our understanding of the molecular pathophysiology of environment-induced severe hypertriglyceridemia. In vivo kinetics studies in humans have indicated that the overproduction of large VLDL is a prominent feature of environment-induced severe hypertriglyceridemia. 8, 9 Molecular studies have identified several genes that control large-VLDL production including LXR, SREBP-1a, and SREBP-1c. 27, 30, 36 However, whether these molecular pathways control hypertriglyceridemia in physiological conditions has not been tested. Our data for the first time demonstrate that a single gene (SREBP-1c) plays an essential role in environment-induced severe hypertriglyceridemia using a disease model of apo AV deficiency. Inhibitors of SREBP is currently under clinical development. 5 CAT-2003 and CAT-2054 are conjugates of eicosapentaenoic acid and niacin and inhibit the maturation of both SREBP-1 and SREBP-2.
56 These compounds are now tested for its efficacy and safety for treating hypercholesterolemia, as well as hypertriglyceridemia. More specific inhibitors of SREBP-1c might be more effective in treating severe hypertriglyceridemia, which deserves further study.
Our study may answer another long-standing enigma of apo AV: how can an apolipoprotein with much lower plasma concentration than VLDL plays a dominant role in VLDL metabolism. 57 The plasma concentration of apo AV (≈100-400 ng/mL) 58, 59 is estimated as only 4% of that of total VLDL particles in plasma. 57 This enigma can be solved, providing that apo AV is required primarily for the clearance of large-VLDL particles of chylomicron size (>80 nm; Figures 1-4) . As large-VLDL particles (>80 nm) constitute only a proportion of total VLDL particles (estimated as <3% of total VLDLs in our data; Figures 1-3) , the concentrations of apo AV (≈4% of total VLDLs) and large-VLDLs (≈3% of total VLDLs) are within the same range. As a molar basis, Merkel et al estimated that about 1 apo AV molecule is present in 24 VLDL particles. 57 Given that large-VLDLs constitute ≈3% of total VLDLs (Figures 1-3 ), 1 apo AV molecule is present in ≈1 large-VLDL particle.
As to the mode of action of apo AV, our results are compatible with the notion that apo AV enhances LPL action by facilitating the interaction between TRL and LPL. However, our results do not preclude the possibility that apo AV enhances whole particle uptake of TRL, 13, 16, 17 or inhibits VLDL secretion via its intracellular role to promote lipid droplet formation. 18, 19 Our study may have several limitations. First, the results presented were performed in male mice, and further validation in female mice is required to assess the possible effect of sex-related confounding factors that affect lipid metabolism. Second, some studies used relatively small numbers of mice (n=4-5) per each group, although we repeated experiments to confirm the results. Third, the underlying molecular mechanisms on the clear rescue of age-related hypertriglyceridemia by SREBP-1c deficiency may involve not only large-VLDL formation but also other factors, such as VLDL secretion rate, which deserves further study. Fourth, our data are compatible with the role of SREBP-1c in large-VLDL formation but do not preclude the possibility that SREBP-1c may play a role in chylomicron formation as well. Further study in tissue-specific mouse models is required to rule out this possibility. Fifth, although our data are consistent with the model whereby apo AV clears large VLDL of chylomicron size, the direct proof by in vitro biochemical approaches requires further study.
In conclusion, our studies uncover a pivotal role of the SREBP-1c large-VLDL pathway in environment-induced severe hypertriglyceridemia. The molecular dissection of gene (apo AV)-environment (SREBP-1c-mediated large-VLDL production) interactions not only expands our understanding of plasma triglyceride homeostasis and hypertriglyceridemia pathogenesis but also offers a brand-new approach to treat severe hypertriglyceridemia by inhibiting genes that mediate environmental effects.
